Total number of shares and voting rights in Zealand Pharma at September 30, 2022
2022年10月1日 - 5:00AM
Company announcement – No. 42 / 2022
Total number of shares and voting rights in Zealand
Pharma at September
30,
2022
Copenhagen, DK and Boston, MA,
September 30,
2022 – Zealand Pharma
A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a
Copenhagen-based biotechnology company focused on the discovery and
development of innovative peptide-based medicines, in accordance
with section 32 of the Danish Capital Markets Act, announces the
total number of shares and voting rights in the Company at the end
of a calendar month during which there have been changes to its
share capital.
In Company announcement No. 39/2022 from September 13, 2022,
Zealand announced an increase in share capital relating to exercise
of employee warrants. Following this announcement, the table below
lists the total number of shares and voting rights in Zealand up to
and including September 30, 2022.
Date |
Number of shares(nominal value of DKK 1
each) |
Share capital(nominal value in
DKK) |
Number of voting rights |
August 31, 2022 |
46,538,186 |
46,538,186 |
46,538,186 |
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology
company focused on the discovery and development of peptide-based
medicines. More than 10 drug candidates invented by Zealand have
advanced into clinical development, of which two have reached the
market and three candidates are in late-stage development. In
addition, license collaborations with Boehringer Ingelheim and
AstraZeneca create opportunities for more patients to potentially
benefit from Zealand-invented peptide investigational agents
currently in development.Zealand was founded in 1998 and is
headquartered in Copenhagen, Denmark, with a presence in the U.S.
that includes Boston. For more information about Zealand’s business
and activities, please visit www.zealandpharma.com.
Forward-Looking StatementThe above information
contains forward-looking statements that provide Zealand Pharma’s
expectations or forecasts of future events, including
forward-looking statements about the termination of the Company’s
ADR program. Such forward-looking statements are subject to risks,
uncertainties and inaccurate assumptions, which may cause actual
results to differ materially from expectations set forth herein and
may cause any or all of such forward-looking statements to be
incorrect. If any or all of such forward-looking statements prove
to be incorrect, our actual results could differ materially and
adversely from those anticipated or implied by such statements. All
such forward-looking statements speak only as of the date of this
release and are based on information available to Zealand Pharma as
of the date of this release. Except as required by law, the Company
assumes no obligation to update these forward-looking statements
publicly.
Contact:
Anna Krassowska,
PhDVice President, Investor Relations & Corporate
CommunicationsZealand PharmaEmail: ank@zealandpharma.comDavid Rosen
(U.S. Media)Argot PartnersEmail:
media@zealandpharma.com |
|
Zealand Pharma AS (NASDAQ:ZEAL)
過去 株価チャート
から 5 2024 まで 6 2024
Zealand Pharma AS (NASDAQ:ZEAL)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Zealand Pharma AS (ナスダック市場): 0 recent articles
その他のニュース記事